Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.

Background: Although endocrine therapies, alone or in combination with CDK4/6 inhibitors, have led to notable improvements in the treatment of estrogen receptor-positive (ER+) breast cancer, progression is inevitable for most patients. We report dose escalation and expansion data from a trial of H3B-6545 (a novel selective ER covalent antagonist that inactivates wild-type and mutant ERα) in women with locally advanced/metastatic ER+, HER2-negative breast cancer (BC).

Methods: This study was a multicenter, open-label, phase 1/2 trial.

Influence of Heat Treatment Parameters on Microhardness of Aluminium Alloy EN AW 7075 Foams and Bulk Material.

Aluminium alloy foams have been widely used due to their excellent strength-to-weight ratio, low density, and outstanding properties such as high energy absorption and effective noise and heat insulation. In this study, aluminium machining chips have been used for foam production as a potential recycling method. The process has involved solution heat treatment followed by artificial ageing.

Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.

The second edition of the Buenos Aires Breast Cancer Symposium (BA-BCS), the first to be held in person, took place from September 3rd to 6th, 2024, in Buenos Aires, Argentina. Nineteen scientists from Brazil, Canada, the United States, the United Kingdom, Denmark, Germany, and Spain, along with six Argentine experts, shared and discussed their recent findings with the audience. Young researchers had the opportunity to present their results through either mini-oral presentations or posters, facilitating oneon-one interactions and the potential for new collaborations.

Emergence of Multidrug-Resistant in a Common Variable Immunodeficiency Patient: Evolution of Resistance Under the Selective Antibiotic Pressure.

is a leading cause of bacterial gastroenteritis worldwide which usually presents as mild, and self-limiting disease in immunocompetent individuals. However, in immunocompromised patients, such as those with common variable immunodeficiency, can cause severe recurrent infections requiring antibiotic treatment. Our study reports a case of a 37-year-old male patient with CVID, who had multiple episodes of intestinal infections over a 3.

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

Background: Inavolisib is a potent and selective PI3Kα inhibitor that promotes degradation of mutated p110α. We report safety from a phase I/Ib dose-escalation/-expansion study (GO39374; NCT03006172) of inavolisib alone or in combination therapies in PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer.

Patients And Methods: Patients received inavolisib [oral once daily (od)] alone, with letrozole (2.